Lennox-Gastaut Syndrome (LGS) Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Lennox-Gastaut Syndrome (LGS) Treatment Market 2024-2028

The Lennox-Gastaut Syndrome (LGS) Treatment Market size is estimated to grow by USD 699.8 million, at a CAGR of 4.29% between 2023 and 2028. 

Identifying the genetic underpinnings of LGS is proving crucial in developing targeted therapies. Mutations in genes such as DEPDC1 and SCN2A have been linked to specific LGS forms, paving the way for personalized treatment approaches. Advanced techniques such as functional magnetic resonance imaging (fMRI) and magnetoencephalography (MEG) provide deeper insights into brain activity during seizures, aiding in diagnosis and guiding treatment interventions.  Moreover, techniques such as deep brain stimulation (DBS) and vagus nerve stimulation (VNS) are emerging as effective options for LGS patients who do not respond well to medications. Furthermore, the identification of biomarkers associated with LGS aids in early diagnosis, monitoring treatment response and predicting outcomes. Biomarkers also play a crucial role in clinical trials as measurable indicators of treatment efficacy. Thus, the advancements in medical research will boost the growth of the market during the forecast period.

Technavio has segmented the market into Type, End-user, and Geography 

• The type segment is classified into non-surgical treatment and surgical treatment
• The end-user segment is classified into hospitals, specialty clinics, and others
• The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

What will be the size of the Lennox-Gastaut Syndrome Treatment Market During the Forecast Period?

To learn more about this report, Download Report Sample

Lennox-Gastaut Syndrome Treatment Market Segmentation by Type, End-user and Geography

Type Analysis 

Non-surgical treatment

The market share growth by the non-surgical treatment segment will be significant during the forecast period. The non-surgical treatments for LGS include medications and ketogenic food. Medications such as valproate, topiramate, and lamotrigine are considered first-line therapies for the treatment of LGS. Felbamate, levetiracetam, rufinamide, and clobazam are the antiseizure medications commonly prescribed as an early non-surgical treatment for LGS.

Get a glance at the market contribution of various segments Download PDF Sample

The non-surgical treatment segment was the largest and was valued at USD 1,715.52 million in 2018. Dietary therapy includes the classic ketogenic diet. The mechanism of action of the ketogenic diet in controlling LGS-related seizures is unknown. However, it is likely to decrease the LGS symptoms by reducing the excitability of the glutamatergic neurons, lowering carbohydrate levels, and inhibiting the inhibition of the mammalian target of rapamycin (mTOR) receptors. The adoption of such treatment options is expected to drive the growth of the non-surgical treatment segment of the market during the forecast period.

End-user 

Hospitals

Effective lennox-gastaut syndrome treatment in hospitals aims to reduce the frequency and severity of seizures, improving the overall quality of life for patients. Seizure control is a primary goal, as uncontrolled seizures can lead to injuries, cognitive decline, and complications. Comprehensive treatment in a hospital setting may involve interventions to address cognitive impairments associated with LGS. Moreover, hospitals may have access to specialized equipment, such as continuous EEG monitoring and advanced imaging technologies, which can aid in the diagnosis and ongoing monitoring of LGS patients. For individuals with LGS who experience motor or developmental delays, hospitals can provide access to rehabilitation services, including physical therapy, occupational therapy, and speech therapy. Thus, these factors will enhance the growth of the hospital segment of the market during the forecast period.

Specialty clinics

Specialty clinics are staffed by healthcare professionals with specialized expertise in managing and treating LGS. This includes neurologists, epileptologists, and other specialists who have in-depth knowledge of the condition and its complexities. Patients in specialty clinics often undergo thorough evaluations, including detailed assessments of seizure types, cognitive function, and behavioral aspects. Specialty clinics often provide psychosocial support services, including counseling and mental health support, to address these aspects of care. Specialty clinics may facilitate connections between patients and families facing similar challenges, creating a supportive community. This networking can provide emotional support and opportunities for shared experiences. Thus, these factors will enhance the growth of the specialty clinics segment of the market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 36% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the lennox-gastaut syndrome treatment market during the forecast period. An increase in the prevalence of LGS and improved diagnostic capabilities drive the demand for lennox-gastaut syndrome treatments in North America. The well-established healthcare infrastructure in North America, including advanced medical facilities, specialized clinics, and research centers, can contribute to the market growth and trends of the regional lennox-gastaut syndrome treatment market. Moreover, collaborations between pharmaceutical companies, research institutions, and healthcare organizations can accelerate the development and commercialization of new lennox-gastaut syndrome treatments. Supportive government initiatives, such as research grants and funding for rare diseases, can encourage investment in lennox-gastaut syndrome treatment development and contribute to regional lennox-gastaut syndrome (LGS) treatment market growth.

For instance, in November 2022, the Food and Drug Administration (FDA) approved FINTEPLA (fenfluramine) oral solution for the treatment of seizures associated with LGS. Favourable regulatory policies and expedited approval processes for novel lennox-gastaut syndrome treatments will encourage pharmaceutical companies to invest in research and development, leading to the growth of the regional market during the forecast period.

Buy Full Report Now

Key Lennox-Gastaut Syndrome Treatment Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The market analysis and report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Akron Childrens Hospital: The company offers Lennox gestalt syndrome treatment which is used for brain, spine, and nervous system problems.

• Amneal Pharmaceuticals Inc.
• Aquestive Therapeutics Inc.
• Bausch Health Companies Inc.
• Cedars Sinai Health System
• Cision US Inc., Eisai Co. Ltd.
• Epilepsy Foundation
• GlaxoSmithKline Plc
• H Lundbeck AS
• Jazz Pharmaceuticals Plc
• Johnson and Johnson
• Lupin Ltd.
• Marinus Pharmaceuticals Inc.
• Sawai Group Holdings Co. Ltd.
• Supernus Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the market growth and forecasting, strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Lennox-Gastaut Syndrome Treatment Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Lennox-Gastaut Syndrome Treatment Market Drivers

Growing awareness of LGS is notably driving the market growth. LGS is a rare, refractory, debilitating type of epilepsy with life-threatening consequences in pediatric patients. Generally, the treatment for LGS depends on the seizure type and requires a broad spectrum of anti-epileptic drugs. Furthermore, adjunctive therapies, along with first-line treatment drugs, are needed to be used for the treatment of LGS. Hence, the identification of LGS in the early stages aids in treating it more effectively. Therefore, government and non-government organizations are focusing on increasing awareness of the early diagnosis and treatment of LGS across the globe.

Furthermore,  organizations such as the LGSF and the EEB are playing a vital role in raising awareness, funding research, and advocating for better patient care. Thus, an increase in the number of organizations and institutes that create awareness about LGS among people is expected to propel the growth of the market during the forecast period.

Significant Lennox-Gastaut Syndrome Treatment Market Trends

Advancements in precision medicine for LGS are an emerging trend shaping the market growth. Precision medicine in LGS involves the use of advanced genomic and molecular profiling to understand the unique genetic and molecular characteristics of individual patients. This helps identify specific mutations or genetic variations that contribute to LGS. The identification of specific genetic or molecular targets associated with LGS allows for the development of targeted therapies. Advancements in pharmacogenomics help predict how individuals respond to certain medications based on their genetic makeup. This information assists healthcare providers in selecting the most suitable and effective medications for LGS patients, minimizing adverse reactions.

In addition to that, the development of companion diagnostics, which are tests that help identify patients who are likely to benefit from a specific treatment, is a key aspect of precision medicine. Companion diagnostics can be integral in LGS treatment by ensuring that patients receive therapies tailored to their individual needs. Thus, the advancements in precision medicine will boost the growth of the market during the market forecast period.

Major Lennox-Gastaut Syndrome Treatment Market Challenges

Difficulty in diagnosing LGS is a significant challenge hindering market growth. An accurate and early diagnosis is required for the effective treatment of LGS. Accurately diagnosing LGS is often arduous to achieve as the characteristics of LGS-related seizures and the features of EEG are not pathognomonic. For example, tonic or atonic drop attacks are characteristic features of LGS, and such drop attacks occur in a large number of patients with sharp slow waves (SSWs). At the same time, such drop attacks are not confirmatory features for the diagnosis of LGS as they are characteristic features of other epileptic syndromes as well.

Furthermore, video recording and EEG recording are required to identify tonic seizures during sleep, along with the recording of surface electromyography. The lack of confirmatory diagnoses and the other problems (which are mentioned above) associated with the currently available diagnostic methods are expected to limit the growth of the market during the forecast period.

Buy Now Full Report

Key Lennox-Gastaut Syndrome Treatment Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market research and growth strategies.

Global Lennox-Gastaut Syndrome Treatment Market Customer Landscape

Segment Overview

The lennox-gastaut syndrome treatment market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest market trends and analysis and market growth analysis opportunities from 2018 to 2028. 

• Type Outlook
  • Non-surgical treatment
  • Surgical treatment

•  End-user Outlook
  • Hospitals
  • Specialty clinics
  • Others

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • The U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina 
    • Australia

Lennox-Gastaut Syndrome Treatment Market Scope
Report Coverage	Details
Page number	161
Base year	2023
Historic period	2018-2022
Market forecasting period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 4.29%
Market Growth 2024-2028	USD 699.8 million
Market structure	Fragmented
YoY growth 2023-2024(%)	3.55
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 36%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Akron Childrens Hospital, Amneal Pharmaceuticals Inc., Aquestive Therapeutics Inc., Bausch Health Companies Inc., Cedars Sinai Health System, Cision US Inc., Eisai Co. Ltd., Epilepsy Foundation, GlaxoSmithKline Plc, H Lundbeck AS, Jazz Pharmaceuticals Plc, Johnson and Johnson, Lupin Ltd., Marinus Pharmaceuticals Inc., Sawai Group Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Lennox-Gastaut Syndrome Treatment Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the lennox-gastaut syndrome treatment market between 2024 and 2028
• Precise estimation of the lennox-gastaut syndrome treatment market size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of lennox-gastaut syndrome treatment market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch